
Progress update on the implementation of the End TB Strategy, and the Global Strategy for TB research and Innovation (WHA73.3)

Dr. Tereza Kasaeva, Director Global TB Programme




It's time to translate commica same





TB affects every country of the world, but its magnitude & impact are greatest in low-and-middle income countries.





- ✓ Approximately 87% of global TB cases are in 30 high TB burden countries
- ✓ Eight countries accounted for 68% of global cases in 2022

TB affects people of all age groups

Men (55%), women (33%), children (12%)





TB REMAINS ONE OF THE TOP



INFECTIOUS KILLERS IN THE WORLD

It is the leading cause of death of people with HIV and a major contributor of antimicrobial resistance related deaths

In 2022,


- 1.3 million people died from TB
- 10.6 million people fell ill with TB
- Two in five people with drug-resistant
 TB did not access treatment

About a quarter of the global population is estimated to have been infected with TB bacteria



Global recovery in reported number of people newly diagnosed with TB


7.5 million in 2022: highest number since WHO started global TB monitoring in mid-1990s





Globally, TB incidence continued to increase


Best estimate of 10.6 million in 2022





Global number of deaths caused by TB

DECREASED in 2022 to 1.3 million




COVID-related disruptions resulted in about half a million excess deaths from TB in 2020, 2021, 2022





GLOBAL ESTIMATES OF TB CASES ATTRIBUTABLE TO 5 RISK FACTORS IN 2022



Number of attributable cases (millions)

- TB is driven by complex health and social determinants such as undernutrition and poverty.
- Approximately half of people who develop TB disease face significant financial hardship because of their illness.




PROGRESS TOWARDS TARGETS





Progress towards targets in the END TB Strategy





Progress towards 2018 UN political declaration targets





Target: 40 million 2018–2022 **34**million (84%)

treated in 2018–2022


TB preventive treatment

Target: 30 million 2018–2022


15.5 million (52%)

treated in 2018–2022

Annual funding, TB services




Annual funding, TB research





Progress with respect to TB research and innovation

Status of clinical development pipeline for diagnostics, drugs and vaccines (August 2023)





new <u>diagnostic products</u> to detect drug-resistant TB recommended by WHO in 2023



28

<u>drugs</u> for treatment of TB disease in clinical trials



16

<u>vaccine</u> candidates in clinical trials


29+

clinical <u>drug</u> trials and other research studies for treatment of TB infection



Progress with respect to TB research and innovation

Examples of progress in 2023



Implementation of the global strategy for TB research and innovation

WHO launch of global individual platform for tuberculosis treatment

WHO launch of TB research tracker, an patient data online platform to track progress in TB research

WHO launch of target product profiles to shape product development towards public health impact

Global research agenda for antimicrobial resistance in human health











For more information: Global TB Report 2023



Full public value assessment of new TB vaccines

Over a 25-year period, a partially effective (50%) TB vaccine for adolescents and adults

Saving lives could cumulatively avert 37.2–76.0 million cases and

4.6–8.5 million deaths

Antimicrobial stewardship could avert 21.9–42.3 million treatments with

saving

antibiotics

Cost-effective and cost- Estimated to be cost-effective in nearly all high TB-

burden countries and cost-saving from a societal

perspective.


Return on investment Would return US \$7 in health and economic benefits

to the economy For every US\$ 1 invested in the full

set of interventions

Market potential The population that requires vaccination could be up

to 1.32–1.43 billion adolescents and adults



https://www.who.int/publications-detail-redirect/9789240064690





HIGH-LEVEL STRATEGIC ROUNDTABLE ON THE **ESTABLISHMENT** OF THE TB VACCINE ACCELERATOR COUNCIL

17 JANUARY 2023 DAVOS, SWITZERLAND



20 SEPTEMBER 2023 NEW YORK, USA





NEW GLOBAL COMMITMENTS

Seventy-eighth session Agenda item 125 Global health and foreign policy

Resolution adopted by the General Assembly on 5 October 2023

[without reference to a Main Committee (A/78/L.4)]

78/5. Political declaration of the high-level meeting on the fight against tuberculosis

The General Assemb

Adopts the political declaration of the high-level meeting on the fight against turnerculosis, held on 22 September 2023 in accordance with its resolution 77/274 of 24 February 2023, as contained in the annex to the present resolution.

16th plenary meeting 5 October 2023

Annex

Political declaration of the high-level meeting on the fight

Advancing science, finance and innovation, and their benefits, to urgently end the global tuberculosis epidemic, in particular by ensuring equitable access to prevention, testing, treatment and care

We, Heads of State and Government and representatives of States and Governments assembled at the United Nations on 22 September 2023 to reaffirm our commitment to end the tuberculosis sipidenic by 2030, and review progress achieved in realizing the 2018 political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis, 'deeply concerned that some of the global targets set at the United Nations high-level meeting might not be reached, alarmed by the adverse impact of the coronavirus disease (COVID-19) pandemic on access to

¹ Resolution 73/3









HIGH LEVEL PARTICIPATION

OVER 600 PARTICIPANTS

>115


Statements

delivered by Head of State and other leaders and ministers



>125

MINISTERS/ COUNTRY DELEGATIONS



>300

CIVIL SOCIETY/
OTHER STAKEHOLDERS

5

UN AGENCIES



Global tuberculosis targets -2023 UNGA political declaration on TB



TB treatment coverage

90% by 2027



Coverage of TB preventive treatment for priority groups (household contacts of people 90% by 2027) with TB; people living with HIV)



Coverage of rapid diagnostic testing for TB

100% by 2027



Coverage of health and social benefits package for people with TB

100% by 2027

Development and availability of new TB vaccines that are safe and effective

Rollout initiated, preferably within 5 years




Annual funding for universal access to quality prevention, diagnosis, treatment and care for TB

US\$ 22 billion by 2027, US\$ 35 billion by 2030



Annual funding for TB research

US\$ 5 billion by 2027



Resolution adopted by the General Assembly on 5 October 2023

[without reference to a Main Committee (A/78/L.4)]

78/5. Political declaration of the high-level meeting on the fight

Adopts the political declaration of the high-level meeting on the fight agains culosis, held on 22 September 2023 in accordance with its resolution 77/274 of

Political declaration of the high-level meeting on the fight against tuberculosis

Advancing science, finance and innovation, and their benefits, to urgently end the global tuberculosis epidemic, in particular by ensuring equitable access to prevention, testing, treatment and car

mmitment to end the tuberculosis epidemic by 2030, and review progress achieve realizing the 2018 political declaration of the high-level meeting of the Genera Assembly on the fight against tuberculosis, deeply concerned that some of the global targets set at the United Nations high-level meeting might not be reached, alarmed by








TRANSLATING COMMITMENTS TO ACTION SUPPORT BY THE SECRETARIAT







RAPID UPTAKE OF WHO POLICIES, TOOLS AND RECOMMENDATIONS















- Living consolidated guidance
 - Rapid updates based on new developments
- Public consultation
- Rapid communication
- Guidelines
 accompanied by
 operational handbooks
 and training courses to
 enable rapid
 implementation



NATIONAL ADAPTATION OF WHO MULTISECTORAL ACCOUNTABILITY FRAMEWORK OPERATIONAL GUIDELINES & BEST PRACTICES





In 2023, 43 % of all countries overall and 73% of those with a high burden of TB reported that they have multisectoral accountability and review mechanisms.



STRENGTHENED COLLABORATION



JOINT STATEMENT: WHO DIRECTOR-GENERAL AND THE CIVIL SOCIETY TASK FORCE ON TB


FOR THE 2023 UNITED NATIONS HIGH-LEVEL MEETING ON **TUBERCULOSIS**




In this Joint Statement, the WHO Director-General and the Civil Society Task Force on TB commend Member States for their efforts in translating commitments in the political declaration of the 2018 United Nations General Assembly high-level meeting on the fight against TB into action, as well as efforts of the ministries of health, community, civil society and other partners and funders for the progress in implementing the commitments.

However, major concerns remain. While some Member States have achieved important milestones towards meeting the End TB Strategy targets, progress is overall very slow and the set global targets have not been achieved. The COVID-19 pandemic, the war in Ukraine and other parts of the world, the global energy crisis, climate change and the impact of these on the broader determinants of TB such as food insecurity will likely worsen the TB epidemic, and its impact on people with or at risk of TB.

This situation is unacceptable, over 4,000 people in the world losing their lives to TB each day, and close to 30,000 people falling ill from TB which is preventable and curable.









Kibuchi

Khan



Ismollova

Acaba

Blessina

Kumar













Phyo



Paran Sarimita Winarni




Chorna

Chamreun Sok



on TB

FOR MORE INFORMATION







THANK YOU!

